FAILURE OF HIGH-DOSE VITAMIN-C (ASCORBIC-ACID) THERAPY TO BENEFIT PATIENTS WITH ADVANCED CANCER - CONTROLLED TRIAL
FAILURE OF HIGH-DOSE VITAMIN-C (ASCORBIC-ACID) THERAPY TO BENEFIT PATIENTS WITH ADVANCED CANCER - CONTROLLED TRIAL
复制标题
DOI：
10.1056/nejm197909273011303
复制
发表时间：
1979-01-01
影响因子：
158.5
通讯作者：
FRYTAK, S
中科院分区：
文献类型：
--
作者：
CREAGAN, ET;MOERTEL, CG;FRYTAK, S
晚期癌症患者（150例）参加了一项对照双盲研究，以评估高剂量维生素C对症状和生存率的影响。患者被随机分为两组，一组接受维生素C（10 g/天），另一组接受无糖风味乳糖安慰剂。可评价患者（60例）接受维生素C治疗，63例接受安慰剂治疗。两组在年龄、性别、原发肿瘤部位、体能评分、肿瘤分级和既往化疗史方面相似。两组在症状、体力状态、食欲或体重变化方面无明显差异。所有患者的中位生存期为. apprx。周，生存曲线基本重叠。在这组选定的患者中，我们无法显示高剂量维生素C治疗的治疗益处。
Patients (150) with advanced cancer participated in a controlled double-blind study to evaluate the effects of high-dose vitamin C on symptoms and survival. Patients were divided randomly into a group that received vitamin C (10 g/day) and one that received a comparably flavored lactose placebo. Evaluable patients (60) received vitamin C and 63 received a placebo. Both groups were similar in age, sex, site of primary tumor, performance score, tumor grade and previous chemotherapy. The 2 groups showed no appreciable difference in changes in symptoms, performance status, appetite or weight. The median survival for all patients was .apprx. wk, and the survival curves essentially overlapped. In this selected group of patients, we were unable to show a therapeutic benefit of high-dose vitamin C treatment.